|
 |
| home > ebr > winter 2002 > target validation in the nervous system using herpes simplex viral vectors |
|
|
 PUBLICATIONS |
European BioPharmaceutical Review
|
| The recent sequencing of the human genome has produced a plethora of potential novel drug targets and candidate genes for gene therapy. New drug discovery using large-scale functional genomics approaches, however, faces the major problem of target validation. Traditionally this has been achieved by pharmacology, using specific antagonists and agonists, or by using transgenic animals, particularly knock-out mice. However, these approaches have considerable drawbacks, being extremely time-consuming, laborious and expensive. This is particularly the case if large numbers of potential target genes are to be tested.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Dr James Palmer, Senior Scientist, and Dr Robert Coffin, Chief Scientific Officer, at BioVex Ltd Dr James Palmer joined BioVex Ltd, a gene delivery and therapeutic vaccine company, in September 1999. He was previously a post-doctoral fellow at University College London in the academic laboratory of BioVex's Founding Scientist and current Research Director, Dr Robert Coffin.
Dr Palmer is currently a Senior Scientist developing herpes simplex viral vector systems for gene delivery to the nervous system for target validation purposes. Prior to this, he obtained his PhD in Molecular Neuroscience from the University of Cambridge working in the Neurobiology Division of the MRC Laboratory of Molecular Biology, and his BSc in Pharmacology from the University of Bristol.
Dr Robert Coffin is a Founding Scientist at Biovex Ltd, Lecturer in Virology and Gene Therapy at University College London (UCL) and Honorary Senior Lecturer at The Institute of Child Health. Following a PhD in Virology at Imperial College, Dr Coffin moved to UCL to develop herpes simplex virus (HSV) based vectors and to study the molecular basis of HSV latency.
During the course of this work - which led to the foundation of Biovex Ltd where he is CSO - vectors were developed that are useful for studying, and potentially treating, neurological disease and for the immune-based treatment of various diseases. Dr Coffin is a world recognised expert in the field of HSV vectorology and latency, and has authored numerous scientific publications.
|
|
|
|
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
MipTec, October 14 – 16, 2008, Switzerland
MipTec about to take off by joining forces between Life Sciences Week, ALL-SystemsX.ch-Day, & Jobvector.com
More info >> |
|
 |
